In a strategic move to expand its pharmaceutical offerings, NLS Pharmaceutics Ltd. has entered into a merger agreement with biotechnology firm Kadimastem Ltd. The merger, announced today, will result in Kadimastem merging into a wholly owned subsidiary of NLS, with the subsidiary surviving as the ongoing entity.
Under the terms of the agreement, each Kadimastem share will be automatically converted into the right to receive a determined number of NLS common shares, with the initial exchange ratio implying that Kadimastem shareholders will own approximately 80% of the combined company's shares on a fully diluted basis, subject to adjustments at closing.
The transaction, which was initially agreed upon on November 4, 2024, aims to leverage the synergies between NLS's expertise in the pharmaceutical preparations sector and Kadimastem's specialization in regenerative medicine.
Investors and shareholders are advised that the financial statements of Kadimastem for the fiscal year ending December 31, 2023, and the six months ending June 30, 2024, along with the pro forma financial statements of NLS, are included in the report filed with the SEC to provide detailed financial insights into the merger.
The merger is subject to regulatory approvals and customary closing conditions. Additional details will be made available in a joint proxy statement/prospectus, which will be filed with the SEC as part of a registration statement on Form F-4. Shareholders of both companies will be provided with the joint proxy statement/prospectus once it becomes available to assist in making informed decisions regarding the transaction.
NLS Pharmaceutics Ltd. is a publicly-traded company on the pharmaceutical preparations industry, headquartered in Zurich, Switzerland. The information reported is based on the company's latest 6-K filing with the Securities and Exchange Commission.
In other recent news, NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced a merger aimed at advancing treatments for neurodegenerative diseases and diabetes. The combined entity will focus on NLS's Dual Orexin Agonist platform and Kadimastem's allogeneic cell therapy program. Post-merger, NLS plans to divest certain legacy assets, with net proceeds distributed to its shareholders and warrant holders.
NLS Pharmaceutics has also announced a 1-for-40 reverse share split, reducing the number of outstanding common shares from approximately 46.88 million to around 1.17 million. This restructuring move is part of the company's ongoing efforts to manage its capital structure.
Furthermore, NLS Pharmaceutics has entered into an agreement to issue and sell over 3 million common shares and issue warrants in a private placement, managed by H.C. Wainwright & Co. The company also reported successful preclinical results for compounds targeting Parkinson's Disease, with plans to develop two new successors, AEX-230 and AEX-231, for neurodegenerative disorders.
InvestingPro Insights
As NLS Pharmaceutics Ltd. (NLSP) embarks on this strategic merger with Kadimastem Ltd., investors should consider some key financial metrics and insights provided by InvestingPro. The company's market capitalization stands at a modest $7.32 million, reflecting its current position in the pharmaceutical industry.
InvestingPro Tips highlight that NLSP has not been profitable over the last twelve months, with an adjusted operating income of -$6.31 million. This aligns with the company's strategic move to merge, potentially seeking to improve its financial position and market presence.
The stock's performance has been challenging, with InvestingPro data showing a significant price decline of 84.49% over the past year. This context makes the merger particularly crucial for NLSP's future prospects. Additionally, with short-term obligations exceeding liquid assets, the merger could potentially provide much-needed financial stability.
For investors considering NLSP's valuation, the Price to Book ratio stands at -0.79, indicating that the market currently values the company below its book value. This could be seen as an opportunity, especially if the merger successfully leverages the combined strengths of both companies.
It's worth noting that InvestingPro offers 7 additional tips for NLSP, providing a more comprehensive analysis for those looking to delve deeper into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.